Clinical Study

Measurement of the Silver Ion Concentration in Wound Fluids after Implantation of Silver-Coated Megaprostheses: Correlation with the Clinical Outcome

Table 1

Demographic descriptions of the patient cohort, the indication for the silver prosthesis, an illustration of the joint concerned, and the total silver mass of the respective prosthesis.

Patient no.Age at the time of surgeryGenderType of fracture/tumorIndication silverType of prosthesisSilver mass (g)

137wSecondary open distal femur fractureInfection Plate osteosynthesisProximal Tibia, distale femur0.76
267mFractured acetabulumInfection THAProximal femur0.62
383wMedial fracture of the femur neckInfection dual head prosthesisProximal femur0.46
473mPeriprosthetic fracture of the femurInfection THAProximal femur1.69
550mMedial fracture of the femur neckInfection dual head prosthesisProximal femur0.46
681wMedial fracture of the femur neckInfection dual head prosthesisProximal femur0.67
783wSubtrochanteric fracture of the femurInfection Plate osteosynthesisProximal femur0.52
889wMedial fracture of the femur neckInfection dual head prosthesisProximal femur0.46
963wPertrochanteric fracture of the femurInfection intramedullary nailProximal femur0.62
1045wSecondary open supracondylar humerus fractureInfection elbow prosthesisDistal humerus, prox. ulna0.4
1146wOsteosarcomaLoosened TKAProximal tibia, distale femur1.33
1255wMetastasis renal cell carcinoma head of the humerusProphylaxisProximal humerus0.42
1364wMetastasis cervix carcinoma distal humerus ProphylaxisDistal humerus, prox. ulna0.95
1471mMetastasis adenoca prox. femurProphylaxisProximal femur1.03
1524mEwing's sarcoma prox. tibiaProphylaxisProximal tibia, distal femur1.24
1666wChondrosarcoma humerusProphylaxisProximal humerus0.97
1724mOsteosarcoma femoral shaftProphylaxisTotal femur0.68
1860wMetastasis mamma ca prox. femurProphylaxisProximal femur0.75

Patients 1–10: infection group; patients 11–18: infection prophylaxis group; g: gram; THA: total hip arthroplasty; TKA: total knee arthroplasty.